Loading
IB
Immix Biopharma, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Morris Gabriel S, was filed 10 Dec 2025.
Insider Decl.
63
Thresholds
n/a
Buy Volume
€1M
42 ops. · all time
Sell Volume
€549
1 ops. · all time
Who traded when
BuySaleGabriel S. Morris3 buys
Ilya M. Rachman3 buys
Jason Hsu2 buys
Since the insiders bought
- +41.7%Entry US$7.38 · Close at T+90 US$10.46
- +41.7%Entry US$7.38 · Close at T+90 US$10.46
- +146.0%Entry US$2.24 · Close at T+365 US$5.51
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$8.28
Analyst consensus
8 analysts1.43/5
US$17.40Target US$24.30(+194%)US$30.00
Income statement
EBITDA-US$29.6M
Net income-US$29.4M0.0% margin
Valuation
PER (forward)-9.8x
P/Book2.6x
Beta0.24
Balance sheet & cash
Market capUS$686M
Total debtUS$1.1M
Free Cash Flow-US$24.7M
Debt / Equity0%
Profitability & ownership
ROE-34.2%
ROA-20.5%
% insiders14.8%
% institutions68.3%
Last declaration on 29 May 2026
Declarations63 total
6,250 shares0Common StockSEC:0001493152-26-026429:0
6,250 shares0Common StockSEC:0001493152-26-026423:0
6,250 shares0Common StockSEC:0001493152-26-026426:0
6,250 shares0Common StockSEC:0001493152-26-026424:0
770 shares@ US$6.581.1% of flowCommon StockSEC:0001493152-25-027107:1
Canonical exit: 10 Mar 2026 (T+90)
746 shares@ US$6.679.0% of flowCommon StockSEC:0001493152-25-027109:0
Canonical exit: 10 Mar 2026 (T+90)
156,000 shares@ US$0.8054.6% of flowCommon StockSEC:0001493152-25-027107:0
2,500 shares@ US$2.029.0% of flowCommon StockSEC:0001493152-25-013919:0
Canonical exit: 16 Dec 2025 (T+90)
2,600 shares@ US$1.972.2% of flowCommon StockSEC:0001493152-25-013918:0
Canonical exit: 15 Dec 2025 (T+90)
2,225 shares@ US$2.2792.3% of flowCommon StockSEC:0001641172-25-015755:0
Canonical exit: 16 Sept 2025 (T+90)
2,178 shares@ US$2.2959.2% of flowCommon StockSEC:0001641172-25-015756:0
Canonical exit: 16 Sept 2025 (T+90)
40,000 shares@ US$2.192.2% of flowCommon StockSEC:0001493152-24-052103:1
Canonical exit: 23 Mar 2025 (T+90)
7,700 shares@ US$2.1660.5% of flowCommon StockSEC:0001493152-24-052103:0
Canonical exit: 20 Mar 2025 (T+90)
8,100 shares@ US$2.250.4% of flowCommon StockSEC:0001493152-24-033900:1
Canonical exit: 20 Nov 2024 (T+90)
15,000 shares@ US$2.2260.9% of flowCommon StockSEC:0001493152-24-033900:0
Canonical exit: 19 Nov 2024 (T+90)
10,000 shares@ US$1.862.1% of flowCommon StockSEC:0001493152-24-033205:0
Canonical exit: 14 Nov 2024 (T+90)
6,000 shares@ US$2.150.3% of flowCommon StockSEC:0001493152-24-029810:1
Canonical exit: 22 Oct 2024 (T+90)
3,200 shares@ US$2.07480.2% of flowCommon StockSEC:0001493152-24-029810:0
Canonical exit: 16 Oct 2024 (T+90)
2,600 shares@ US$2.1310.7% of flowCommon StockSEC:0001493152-24-023287:0
Canonical exit: 5 Sept 2024 (T+90)
2,500 shares@ US$2.11922.5% of flowCommon StockSEC:0001493152-24-023288:0
Canonical exit: 5 Sept 2024 (T+90)
3,300 shares@ US$1.80992.8% of flowCommon StockSEC:0001493152-24-022654:0
Canonical exit: 2 Sept 2024 (T+90)
3,300 shares@ US$1.809111.5% of flowCommon StockSEC:0001493152-24-022653:0
Canonical exit: 2 Sept 2024 (T+90)
1,127 sharesCommon StockSEC:0001493152-24-020779:1
74,241 sharesCommon StockSEC:0001493152-24-020777:1
21,155 sharesCommon StockSEC:0001493152-24-020781:1
25 of 63 declarations
About Immix Biopharma, Inc.
At Immix Biopharma, Inc., nearly everything is a purchase: 40 open-market purchases worth EUR 1,153,157 (median EUR 11,509) and a single sale of EUR 549, by Sean Senn on July 14, 2022. Jason Hsu (Director) filed 14 filings including 13 purchases, and signs the three largest: EUR 222,350 on December 20, 2021, EUR 134,473 on December 11, 2023 and EUR 113,068 on December 8, 2023. Ilya M. Rachman (CEO and Chairman) has 10 purchases among 11 filings, Gabriel S. Morris (CFO) 7 among 14, Magda Marquet (Director) 3 among 5.
From August 31, 2023 to September 15, 2023, 5 filers bought for EUR 362,136. Across the full history, 25 purchase filings are classed as clustered. Purchases are 98% of open-market trades.
Read moreShow less
The record gathers 61 filings from 12 filers, including 15 grants, published between December 20, 2021 and May 29, 2026. 2024 is the busiest year, with 22 filings. The US health care company is valued at USD 686 million, with 14.8% held by insiders. The last twelve months have 6 filings, 1 of them a purchase. For 32 purchases with a result, the 90-day median is -2.3%, with 41% of results positive (recorded past results, not a forecast).
